Inhalers like Spiriva and Advair are too expensive for many Medicare beneficiaries with chronic obstructive pulmonary disease, reports Kaiser Health News. Here are four things to know. 1.
WASHINGTON, Sept 23 (Reuters) - The blockbuster inhaled lung medication Spiriva, marketed by Pfizer Inc and Boehringer Ingelheim, raises the risk of heart attack, stroke and death from heart disease, ...
Please provide your email address to receive an email when new articles are posted on . A Montreal Cognitive Assessment score of 16 or less, which implies dementia, predicted errors in using inhalers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results